Core Insights - Ascentage Pharma Group International is a global, commercial stage biopharmaceutical company focused on developing novel therapies for cancer treatment [2][3] Company Overview - Ascentage Pharma has a rich pipeline of innovative drug products targeting key apoptotic pathway proteins and next-generation kinase inhibitors [2] - The company has established global partnerships with leading biotechnology and pharmaceutical firms, including Takeda, AstraZeneca, Merck, and Pfizer [5] Product Portfolio - The first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor for chronic myeloid leukemia (CML) patients with T315I mutations, covered by the China National Reimbursement Drug List [3] - The second approved product, Lisaftoclax, is a Bcl-2 inhibitor for hematologic malignancies, currently undergoing multiple global registrational Phase III trials [4] Upcoming Events - Company management plans to present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 [1]
Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference